Bispecific antibodies as a development platform for new concepts and treatment strategies

International Journal of Molecular Sciences

Volumn 18, Issue 1, 2017, Pages

  Yang, Fa ^a   Wen, Weihong ^b   Qin, Weijun ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Angiogenesis inhibitors; Bispecific antibodies; Bispecific T cell engagers (BiTEs); Delivery system; Drug resistance; Immunological synapse; Immunotherapy

Indexed keywords

AFM 11; AFM13; AMG 112; BISPECIFIC ANTIBODY; BLINATUMOMAB; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; CATUMAXOMAB; CYTOTOXIC AGENT; DIPHTHERIA TOXIN; DOXORUBICIN; DT 2219; DT 2219ARL; ERTUMAXOMAB; FBTA 05; MGD 006; MM 111; MT 110; MT 111; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOID LEUKEMIA; ANGIOGENESIS; ANTIBODY ENGINEERING; ANTIBODY SPECIFICITY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL; CELLULAR IMMUNITY; CYTOTOXICITY; DRUG RESISTANCE; GASTROINTESTINAL CARCINOMA; HODGKIN DISEASE; HUMAN; IMMUNE RESPONSE; MALIGNANT ASCITES; MOLECULAR CLONING; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; RADIOIMMUNOTHERAPY; REVIEW; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; PROCEDURES;

ANIMALS; ANTIBODIES, BISPECIFIC; HUMANS; IMMUNOTHERAPY;

EID: 85008223150     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms18010048     Document Type: Review

References (105)

1. Elgundi, Z., Reslan, M., Cruz, E., Sifniotis, V., Kayser, V. The state-of-play and future of antibody therapeutics. Adv. Drug Deliv. Rev. 2016. [CrossRef] [PubMed]
2. Alexander, P.B., Chen, R., Gong, C., Yuan, L., Jasper, J.S., Ding, Y., Markowitz, G.J., Yang, P., Xu, X., McDonnell, D.P., et al. Distinct receptor tyrosine kinase subsets mediate anti-HER2 drug resistance in breast cancer. J. Biol. Chem. 2016. [CrossRef] [PubMed]
3. Merchant, A.M., Zhu, Z., Yuan, J.Q., Goddard, A., Adams, C.W., Presta, L.G., Carter, P. An efficient route to human bispecific IgG. Nat. Biotechnol. 1998, 16, 677-681. [CrossRef] [PubMed]
4. Coloma, M.J., Morrison, S.L. Design and production of novel tetravalent bispecific antibodies. Nat. Biotechnol. 1997, 15, 159-163. [CrossRef] [PubMed]
5. Ridgway, J.B., Presta, L.G., Carter, P. “Knobs-into-holes” engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng. 1996, 9, 617-621. [CrossRef] [PubMed]
6. Lindhofer, H., Mocikat, R., Steipe, B., Thierfelder, S. Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J. Immunol. 1995, 155, 219-225. [PubMed]
7. Orlandi, R., Gussow, D.H., Jones, P.T., Winter, G. Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proc. Natl. Acad. Sci. USA 1989, 86, 3833-3837. [CrossRef] [PubMed]
8. Loffler, A., Kufer, P., Lutterbuse, R., Zettl, F., Daniel, P.T., Schwenkenbecher, J.M., Riethmuller, G., Dorken, B., Bargou, R.C. A recombinant bispecific single-chain antibody, CD19 × CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 2000, 95, 2098-2103. [PubMed]
9. Nagorsen, D., Kufer, P., Baeuerle, P.A., Bargou, R. Blinatumomab: A historical perspective. Pharmacol. Ther. 2012, 136, 334-342. [CrossRef] [PubMed]
10. Brandl, C., Haas, C., D Argouges, S., Fisch, T., Kufer, P., Brischwein, K., Prang, N., Bargou, R., Suzich, J., Baeuerle, P.A., et al. The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct. Cancer Immunol. Immunother. 2007, 56, 1551-1563. [CrossRef] [PubMed]
11. Moore, P.A., Zhang, W., Rainey, G.J., Burke, S., Li, H., Huang, L., Gorlatov, S., Veri, M.C., Aggarwal, S., Yang, Y., et al. Application of dual affinity retargeting molecules to achieve optimal redirected T cell killing of B cell lymphoma. Blood 2011, 117, 4542-4551. [CrossRef] [PubMed]
12. Reusch, U., Burkhardt, C., Fucek, I., le Gall, F., le Gall, M., Hoffmann, K., Knackmuss, S.H., Kiprijanov, S., Little, M., Zhukovsky, E.A. A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells. mAbs 2014, 6, 727-738. [CrossRef] [PubMed]
13. Reusch, U., Harrington, K., Gudgeon, C., Fucek, I., Ellwanger, K., Weichel, M., Knackmuss, S., Zhukovsky, E., Fox, J.A., Kunkel, L.A., et al. Characterization of CD33/CD3 tetravalent bispecific tandem diabodies (TandAbs) for the treatment of acute myeloid leukemia. Clin. Cancer Res. 2016, 22, 5829-5838. [CrossRef] [PubMed]
14. Reusch, U., Duell, J., Ellwanger, K., Herbrecht, C., Knackmuss, S.H., Fucek, I., Eser, M., McAleese, F., Molkenthin, V., le Gall, F., et al. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19+ tumor cells. mAbs 2015, 7, 584-604. [CrossRef] [PubMed]
15. Kontermann, R.E., Brinkmann, U. Bispecific antibodies. Drug Discov. Today 2015, 20, 838-847. [CrossRef] [PubMed]
16. Offner, S., Hofmeister, R., Romaniuk, A., Kufer, P., Baeuerle, P.A. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol. Immunol. 2006, 43, 763-771. [CrossRef] [PubMed]
17. Bacac, M., Fauti, T., Sam, J., Colombetti, S., Weinzierl, T., Ouaret, D., Bodmer, W., Lehmann, S., Hofer, T., Hosse, R.J., et al. A novel carcinoembryonic antigen T cell bispecific antibody (CEA TCB) for the treatment of solid tumors. Clin. Cancer Res. 2016, 22, 3286-3297. [CrossRef] [PubMed]
18. Stieglmaier, J., Benjamin, J., Nagorsen, D. Utilizing the bite (bispecific T cell engager) platform for immunotherapy of cancer. Expert Opin. Biol. Ther. 2015, 15, 1093-1099. [CrossRef] [PubMed]
19. Topp, M.S., Gokbuget, N., Stein, A.S., Zugmaier, G., O’Brien, S., Bargou, R.C., Dombret, H., Fielding, A.K., Heffner, L., Larson, R.A., et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: A multicentre, single-arm, phase 2 study. Lancet Oncol. 2015, 16, 57-66. [CrossRef]
20. McDonagh, C.F., Huhalov, A., Harms, B.D., Adams, S., Paragas, V., Oyama, S., Zhang, B., Luus, L., Overland, R., Nguyen, S., et al. Antitumor activity of a novel bispecific antibody that targets the ERBB2/ERBB3 oncogenic unit and inhibits heregulin-induced activation of ERBB3. Mol. Cancer Ther. 2012, 11, 582-593. [CrossRef] [PubMed]
21. Vincent, K.J., Zurini, M. Current strategies in antibody engineering: FC engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates. Biotechnol. J. 2012, 7, 1444-1450. [CrossRef] [PubMed]
22. Lobner, E., Traxlmayr, M.W., Obinger, C., Hasenhindl, C. Engineered IgG1-FC—One fragment to bind them all. Immunol. Rev. 2016, 270, 113-131. [CrossRef] [PubMed]
23. Subedi, G.P., Hanson, Q.M., Barb, A.W. Restricted motion of the conserved immunoglobulin G1 N-glycan is essential for efficient FcrIIIa binding. Structure 2014, 22, 1478-1488. [CrossRef] [PubMed]
24. Yamane-Ohnuki, N., Satoh, M. Production of therapeutic antibodies with controlled fucosylation. mAbs 2009, 1, 230-236. [CrossRef] [PubMed]
25. Roopenian, D.C., Akilesh, S. FcRn: The neonatal FC receptor comes of age. Nat. Rev. Immunol. 2007, 7, 715-725. [CrossRef] [PubMed]
26. Ying, T., Ju, T.W., Wang, Y., Prabakaran, P., Dimitrov, D.S. Interactions of IgG1 CH2 and CH3 domains with FcRn. Front. Immunol. 2014, 5. [CrossRef] [PubMed]
27. Tustian, A.D., Endicott, C., Adams, B., Mattila, J., Bak, H. Development of purification processes for fully human bispecific antibodies based upon modification of protein a binding avidity. mAbs 2016, 8, 828-838. [CrossRef] [PubMed]
28. Gunasekaran, K., Pentony, M., Shen, M., Garrett, L., Forte, C., Woodward, A., Ng, S.B., Born, T., Retter, M., Manchulenko, K., et al. Enhancing antibody fc heterodimer formation through electrostatic steering effects: Applications to bispecific molecules and monovalent IgG. J. Biol. Chem. 2010, 285, 19637-19646. [CrossRef] [PubMed]
29. Spiess, C., Merchant, M., Huang, A., Zheng, Z., Yang, N.-Y., Peng, J., Ellerman, D., Shatz, W., Reilly, D., Yansura, D.G., et al. Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies. Nat. Biotechnol. 2013, 31, 753-758. [CrossRef] [PubMed]
30. Schaefer, W., Regula, J.T., Bahner, M., Schanzer, J., Croasdale, R., Durr, H., Gassner, C., Georges, G., Kettenberger, H., Imhof-Jung, S., et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc. Natl. Acad. Sci. USA 2011, 108, 11187-11192. [CrossRef] [PubMed]
31. Wu, C., Ying, H., Grinnell, C., Bryant, S., Miller, R., Clabbers, A., Bose, S., McCarthy, D., Zhu, R.-R., Santora, L., et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat. Biotechnol. 2007, 25, 1290-1297. [CrossRef] [PubMed]
32. Jakob, C.G., Edalji, R., Judge, R.A., DiGiammarino, E., Li, Y., Gu, J., Ghayur, T. Structure reveals function of the dual variable domain immunoglobulin (DVD-IG) molecule. mAbs 2013, 5, 358-363. [CrossRef] [PubMed]
33. Dmitriev, O.Y., Lutsenko, S., Muyldermans, S. Nanobodies as probes for protein dynamicsin vitro and in cells. J. Biol. Chem. 2016, 291, 3767-3775. [CrossRef] [PubMed]
34. Li, A., Xing, J., Li, L., Zhou, C., Dong, B., He, P., Li, Q., Wang, Z. A single-domain antibody-linked fab bispecific antibody HER2-S-FAB has potent cytotoxicity against HER2-expressing tumor cells. AMB Express 2016, 6. [CrossRef] [PubMed]
35. Li, L., He, P., Zhou, C., Jing, L., Dong, B., Chen, S., Zhang, N., Liu, Y., Miao, J., Wang, Z., et al. A novel bispecific antibody, S-fab, induces potent cancer cell killing. J. Immunother. 2015, 38, 350-356. [CrossRef] [PubMed]
36. Wang, L., He, Y., Zhang, G., Ma, J., Liu, C., He, W., Wang, W., Han, H., Boruah, B.M., Gao, B. Retargeting T cells for HER2-positive tumor killing by a bispecific FV-FC antibody. PLoS ONE 2013, 8, e75589. [CrossRef] [PubMed]
37. Wozniak-Knopp, G., Bartl, S., Bauer, A., Mostageer, M., Woisetschlager, M., Antes, B., Ettl, K., Kainer, M., Weberhofer, G., Wiederkum, S., et al. Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: FC fragments with engineered HER2/NEU-binding sites and antibody properties. Protein Eng. Des. Sel. 2010, 23, 289-297. [CrossRef] [PubMed]
38. Lehmann, S., Perera, R., Grimm, H.P., Sam, J., Colombetti, S., Fauti, T., Fahrni, L., Schaller, T., Freimoser-Grundschober, A., Zielonka, J., et al. In vivo imaging of the activity of CEA TCB, a novel T cell bispecific antibody, reveals specific tumor targeting and fast induction of T cell mediated tumor killing. Clin. Cancer Res. 2016, 22, 4417-4427. [CrossRef] [PubMed]
39. Li, J.Y., Perry, S.R., Muniz-Medina, V., Wang, X., Wetzel, L.K., Rebelatto, M.C., Hinrichs, M.J.M., Bezabeh, B.Z., Fleming, R.L., Dimasi, N., et al. A biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy. Cancer Cell 2016, 29, 117-129. [CrossRef] [PubMed]
40. Sengers, B.G., McGinty, S., Nouri, F.Z., Argungu, M., Hawkins, E., Hadji, A., Weber, A., Taylor, A., Sepp, A. Modeling bispecific monoclonal antibody interaction with two cell membrane targets indicates the importance of surface diffusion. mAbs 2016, 8, 905-915. [CrossRef] [PubMed]
41. Boutros, C., Tarhini, A., Routier, E., Lambotte, O., Ladurie, F.L., Carbonnel, F., Izzeddine, H., Marabelle, A., Champiat, S., Berdelou, A., et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat. Rev. Clin. Oncol. 2016, 13, 473-486. [CrossRef] [PubMed]
42. Hoffmann, P., Hofmeister, R., Brischwein, K., Brandl, C., Crommer, S., Bargou, R., Itin, C., Prang, N., Baeuerle, P.A. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int. J. Cancer 2005, 115, 98-104. [CrossRef] [PubMed]
43. Tsai, P., Thayer, W.O., Liu, L., Silvestri, G., Nordstrom, J.L., Garcia, J.V. CD19 × CD3 dart protein mediates human B cell depletion in vivo in humanized blt mice. Mol. Ther. Oncol. 2016, 3, 15024. [CrossRef] [PubMed]
44. Przepiorka, D., Ko, C.W., Deisseroth, A., Yancey, C.L., Candau-Chacon, R., Chiu, H.J., Gehrke, B.J., Gomez-Broughton, C., Kane, R.C., Kirshner, S., et al. FDA approval: Blinatumomab. Clin. Cancer Res. 2015, 21, 4035-4039. [CrossRef] [PubMed]
45. Klinger, M., Brandl, C., Zugmaier, G., Hijazi, Y., Bargou, R.C., Topp, M.S., Gokbuget, N., Neumann, S., Goebeler, M., Viardot, A., et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific bite antibody blinatumomab. Blood 2012, 119, 6226-6233. [CrossRef] [PubMed]
46. Klinger, M., Benjamin, J., Kischel, R., Stienen, S., Zugmaier, G. Harnessing T cells to fight cancer with bite(r) antibody constructs—Past developments and future directions. Immunol. Rev. 2016, 270, 193-208. [CrossRef] [PubMed]
47. Brischwein, K., Schlereth, B., Guller, B., Steiger, C., Wolf, A., Lutterbuese, R., Offner, S., Locher, M., Urbig, T., Raum, T., et al. Mt110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. . 2006, 43, 1129-1143. [CrossRef] [PubMed]
48. Osada, T., Hsu, D., Hammond, S., Hobeika, A., Devi, G., Clay, T.M., Lyerly, H.K., Morse, M.A. Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T cell killing mediated by CEA/CD3-bispecific T cell-engaging bite antibody. Br. J. Cancer 2010, 102, 124-133. [CrossRef] [PubMed]
49. Oberst, M.D., Fuhrmann, S., Mulgrew, K., Amann, M., Cheng, L., Lutterbuese, P., Richman, L., Coats, S., Baeuerle, P.A., Hammond, S.A. CEA/CD3 bispecific antibody Medi-565/Amg 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas. mAbs 2014, 6, 1571-1584. [CrossRef] [PubMed]
50. Friedrich, M., Raum, T., Lutterbuese, R., Voelkel, M., Deegen, P., Rau, D., Kischel, R., Hoffmann, P., Brandl, C., Schuhmacher, J., et al. Regression of human prostate cancer xenografts in mice by Amg 212/Bay2010112, a novel PSMA/CD3-bispecific bite antibody cross-reactive with non-human primate antigens. Mol. Cancer Ther. 2012, 11, 2664-2673. [CrossRef] [PubMed]
51. Al-Hussaini, M., Rettig, M.P., Ritchey, J.K., Karpova, D., Uy, G.L., Eissenberg, L.G., Gao, F., Eades, W.C., Bonvini, E., Chichili, G.R., et al. Targeting CD123 in acute myeloid leukemia using a T cell-directed dual-affinity retargeting platform. Blood 2016, 127, 122-131. [CrossRef] [PubMed]
52. Rothe, A., Sasse, S., Topp, M.S., Eichenauer, D.A., Hummel, H., Reiners, K.S., Dietlein, M., Kuhnert, G., Kessler, J., Buerkle, C., et al. A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory hodgkin lymphoma. Blood 2015, 125, 4024-4031. [CrossRef] [PubMed]
53. Seimetz, D., Lindhofer, H., Bokemeyer, C. Development and approval of the trifunctional antibody catumaxomab (anti-EPCAM × anti-CD3) as a targeted cancer immunotherapy. Cancer Treat. Rev. 2010, 36, 458-467. [CrossRef] [PubMed]
54. Kurbacher, C.M., Horn, O., Kurbacher, J.A., Herz, S., Kurbacher, A.T., Hildenbrand, R., Bollmann, R. Outpatient intraperitoneal catumaxomab therapy for malignant ascites related to advanced gynecologic neoplasms. Oncologist 2015, 20, 1333-1341. [CrossRef] [PubMed]
55. Diermeier-Daucher, S., Ortmann, O., Buchholz, S., Brockhoff, G. Trifunctional antibody ertumaxomab: Non-immunological effects on HER2 receptor activity and downstream signaling. mAbs 2014, 4, 614-622. [CrossRef] [PubMed]
56. Schuster, F.R., Stanglmaier, M., Woessmann, W., Winkler, B., Siepermann, M., Meisel, R., Schlegel, P.G., Hess, J., Lindhofer, H., Borkhardt, A., et al. Immunotherapy with the trifunctional anti-CD20 × anti-CD3 antibody FBTA05 (lymphomun) in paediatric high-risk patients with recurrent CD20-positive b cell malignancies. Br. J. Haematol. 2015, 169, 90-102. [CrossRef] [PubMed]
57. Vallera, D.A., Chen, H., Sicheneder, A.R., Panoskaltsis-Mortari, A., Taras, E.P. Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic b cell malignancy. Leuk. Res. 2009, 33, 1233-1242. [CrossRef] [PubMed]
58. Bachanova, V., Frankel, A.E., Cao, Q., Lewis, D., Grzywacz, B., Verneris, M.R., Ustun, C., Lazaryan, A., McClune, B., Warlick, E.D., et al. Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B cell malignancies. Clin. Cancer Res. 2015, 21, 1267-1272. [CrossRef] [PubMed]
59. Cioffi, M., Dorado, J., Baeuerle, P.A., Heeschen, C. Epcam/CD3-bispecific T cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells. Clin. Cancer Res. 2012, 18, 465-474. [CrossRef] [PubMed]
60. Johnson, S., Burke, S., Huang, L., Gorlatov, S., Li, H., Wang, W., Zhang, W., Tuaillon, N., Rainey, J., Barat, B., et al. Effector cell recruitment with novel FV-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B cell depletion. J. Mol. Biol. 2010, 399, 436-449. [CrossRef] [PubMed]
61. Stadler, C.R., Bähr-Mahmud, H., Plum, L.M., Schmoldt, K., Kölsch, A.C., Türeci, Ö., Sahin, U. Characterization of the first-in-class T cell-engaging bispecific single-chain antibody for targeted immunotherapy of solid tumors expressing the oncofetal protein claudin 6. OncoImmunology 2015, 5, e1091555. [CrossRef] [PubMed]
62. Schmohl, J.U., Felices, M., Taras, L., Miller, J.S., Vallera, D.A. Enhanced ADCC and NK cell activation of an anti-carcinoma bispecific antibody by genetic insertion of a modified IL-15 cross-linker. Mol. Ther. 2016, 24, 1312-1322. [CrossRef] [PubMed]
63. Von Strandmann, E.P., Hansen, H.P., Reiners, K.S., Schnell, R., Borchmann, P., Merkert, S., Simhadri, V.R., Draube, A., Reiser, M., Purr, I., et al. A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates nk cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo. Blood 2006, 107, 1955-1962. [CrossRef] [PubMed]
64. Vyas, M., Schneider, A.C., Shatnyeva, O., Reiners, K.S., Tawadros, S., Kloess, S., Kohl, U., Hallek, M., Hansen, H.P., Pogge von Strandmann, E. Mono-and dual-targeting triplebodies activate natural killer cells and have anti-tumor activity in vitro and in vivo against chronic lymphocytic leukemia. Oncoimmunology 2016, 5, e1211220. [CrossRef] [PubMed]
65. Wang, T., Sun, F., Xie, W., Tang, M., He, H., Jia, X., Tian, X., Wang, M., Zhang, J. A bispecific protein RG7S-mica recruits natural killer cells and enhances NKG2D-mediated immunosurveillance against hepatocellular carcinoma. Cancer Lett. 2016, 372, 166-178. [CrossRef] [PubMed]
66. Borlak, J., Langer, F., Spanel, R., Schondorfer, G., Dittrich, C. Immune-mediated liver injury of the cancer therapeutic antibody catumaxomab targeting EpCAM, CD3 and Fc receptors. Oncotarget 2016. [CrossRef] [PubMed]
67. Schreiner, J., Thommen, D.S., Herzig, P., Bacac, M., Klein, C., Roller, A., Belousov, A., Levitsky, V., Savic, S., Moersig, W., et al. Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor. Oncoimmunology 2016, 5, e1062969. [CrossRef] [PubMed]
68. Köhnke, T., Krupka, C., Tischer, J., Knösel, T., Subklewe, M. Increase of PD-L1 expressing B-precursor all cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab. J. Hematol. Oncol. 2015, 8. [CrossRef] [PubMed]
69. Krupka, C., Kufer, P., Kischel, R., Zugmaier, G., Lichtenegger, F.S., Kohnke, T., Vick, B., Jeremias, I., Metzeler, K.H., Altmann, T., et al. Blockade of the PD-1/PD-l1 axis augments lysis of aml cells by the CD33/CD3 bite antibody construct Amg 330: Reversing a T cell-induced immune escape mechanism. Leukemia 2016, 30, 484-491. [CrossRef] [PubMed]
70. Kalathil, S., Lugade, A.A., Miller, A., Iyer, R., Thanavala, Y. Higher frequencies of GARP+CTLA-4+FOXP3+ T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T cell functionality. Cancer Res. 2013, 73, 2435-2444. [CrossRef] [PubMed]
71. Yano, H., Thakur, A., Tomaszewski, E.N., Choi, M., Deol, A., Lum, L.G. Ipilimumab augments antitumor activity of bispecific antibody-armed T cells. J. Transl. Med. 2014, 12, 191. [CrossRef] [PubMed]
72. Bhutani, D., Lum, L.G. Activated T cells armed with bispecific antibodies kill tumor targets. Curr. Opin. Hematol. 2015, 22, 476-483. [CrossRef] [PubMed]
73. Zitron, I.M., Thakur, A., Norkina, O., Barger, G.R., Lum, L.G., Mittal, S. Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies. BMC Cancer 2013, 13, 83. [CrossRef] [PubMed]
74. Lum, L.G., Thakur, A., Al-Kadhimi, Z., Colvin, G.A., Cummings, F.J., Legare, R.D., Dizon, D.S., Kouttab, N., Maizel, A., Colaiace, W., et al. Targeted T cell therapy in stage IV breast cancer: A phase I clinical trial. Clin. Cancer Res. 2015, 21, 2305-2314. [CrossRef] [PubMed]
75. Urbanska, K., Lynn, R.C., Stashwick, C., Thakur, A., Lum, L.G., Powell, D.J. Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells. J. Transl. Med. 2014, 12, 347. [CrossRef] [PubMed]
76. Roybal, K.T., Williams, J.Z., Morsut, L., Rupp, L.J., Kolinko, I., Choe, J.H., Walker, W.J., McNally, K.A., Lim, W.A. Engineering T cells with customized therapeutic response programs using synthetic notch receptors. Cell 2016, 167, 419-432. [CrossRef] [PubMed]
77. Dengl, S., Sustmann, C., Brinkmann, U. Engineered hapten-binding antibody derivatives for modulation of pharmacokinetic properties of small molecules and targeted payload delivery. Immunol. Rev. 2016, 270, 165-177. [CrossRef] [PubMed]
78. Metz, S., Haas, A.K., Daub, K., Croasdale, R., Stracke, J., Lau, W., Georges, G., Josel, H.P., Dziadek, S., Hopfner, K.P., et al. Bispecific digoxigenin-binding antibodies for targeted payload delivery. Proc. Natl. Acad. Sci. USA 2011, 108, 8194-8199. [CrossRef] [PubMed]
79. Thorey, I.S., Grote, M., Mayer, K., Brinkmann, U. Hapten-binding bispecific antibodies for the targeted delivery of siRNA and siRNA-containing nanoparticles. Methods Mol. Biol. 2016, 1364, 219-234. [PubMed]
80. Schneider, B., Grote, M., John, M., Haas, A., Bramlage, B., Lckenstein, L.M., Jahn-Hofmann, K., Bauss, F., Cheng, W., Croasdale, R., et al. Targeted siRNA delivery and mRNA knockdown mediated by bispecific digoxigenin-binding antibodies. Mol. Ther. Nucleic Acids 2012, 1, e45. [CrossRef] [PubMed]
81. Cheal, S.M., Xu, H., Guo, H.F., Zanzonico, P.B., Larson, S.M., Cheung, N.K. Preclinical evaluation of multistep targeting of diasialoganglioside GD2 using an IgG-SCFV bispecific antibody with high affinity for GD2 and dota metal complex. Mol. Cancer Ther. 2014, 13, 1803-1812. [CrossRef] [PubMed]
82. Cheal, S.M., Xu, H., Guo, H.-F., Lee, S.-G., Punzalan, B., Chalasani, S., Fung, E.K., Jungbluth, A., Zanzonico, P.B., Carrasquillo, J.A., et al. Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity 86Y-or 177LU-Dota-BN binding SCFV C825/GPA33 IgG bispecific immunoconjugates. Eur. J. Nucl. Med. Mol. Imaging 2016, 43, 925-937. [CrossRef] [PubMed]
83. MacDiarmid, J.A., Mugridge, N.B., Weiss, J.C., Phillips, L., Burn, A.L., Paulin, R.P., Haasdyk, J.E., Dickson, K.A., Brahmbhatt, V.N., Pattison, S.T., et al. Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics. Cancer Cell 2007, 11, 431-445. [CrossRef] [PubMed]
84. Solomon, B.J., Desai, J., Rosenthal, M., McArthur, G.A., Pattison, S.T., Pattison, S.L., MacDiarmid, J., Brahmbhatt, H., Scott, A.M. A first-time-in-human phase I clinical trial of bispecific antibody-targeted, paclitaxel-packaged bacterial minicells. PLoS ONE 2015, 10, e0144559. [CrossRef] [PubMed]
85. Poovassery, J.S., Kang, J.C., Kim, D., Ober, R.J., Ward, E.S. Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer. Int. J. Cancer 2015, 137, 267-277. [CrossRef] [PubMed]
86. Picarda, E., Ohaegbulam, K.C., Zang, X. Molecular pathways: Targeting B7-H3 (CD276) for human cancer immunotherapy. Clin. Cancer Res. 2016, 22, 3425-3431. [CrossRef] [PubMed]
87. Loo, D., Alderson, R.F., Chen, F.Z., Huang, L., Zhang, W., Gorlatov, S., Burke, S., Ciccarone, V., Li, H., Yang, Y., et al. Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity. Clin. Cancer Res. 2012, 18, 3834-3845. [CrossRef] [PubMed]
88. Ma, J., Ma, P., Zhao, C., Xue, X., Han, H., Liu, C., Tao, H., Xiu, W., Cai, J., Zhang, M. B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy. Oncotarget 2016. [CrossRef] [PubMed]
89. Lin, L., Bivona, T.G. Mechanisms of resistance to epidermal growth factor receptor inhibitors and novel therapeutic strategies to overcome resistance in nsclc patients. Chemother. Res. Pract. 2012, 2012, 1-9. [CrossRef] [PubMed]
90. Lee, J.M., Lee, S.H., Hwang, J.W., Oh, S.J., Kim, B., Jung, S., Shim, S.H., Lin, P.W., Lee, S.B., Cho, M.Y., et al. Novel strategy for a bispecific antibody: Induction of dual target internalization and degradation. Oncogene 2016, 35, 4437-4446. [CrossRef] [PubMed]
91. Ratner, M. Genentech discloses safety concerns over avastin. Nat. Biotechnol. 2004, 22, 1198. [CrossRef] [PubMed]
92. Chae, S.S., Kamoun, W.S., Farrar, C.T., Kirkpatrick, N.D., Niemeyer, E., de Graaf, A.M.A., Sorensen, A.G., Munn, L.L., Jain, R.K., Fukumura, D. Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas. Clin. Cancer Res. 2010, 16, 3618-3627. [CrossRef] [PubMed]
93. Abdullah, S.E., Perez-Soler, R. Mechanisms of resistance to vascular endothelial growth factor blockade. Cancer 2012, 118, 3455-3467. [CrossRef] [PubMed]
94. Kloepper, J., Riedemann, L., Amoozgar, Z., Seano, G., Susek, K., Yu, V., Dalvie, N., Amelung, R.L., Datta, M., Song, J.W., et al. Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. Proc. Natl. Acad. Sci. USA 2016, 113, 4476-4481. [CrossRef] [PubMed]
95. Lee, D., Kim, D., Choi, Y.B., Kang, K., Sung, E.S., Ahn, J.H., Goo, J., Yeom, D.H., Jang, H.S., Moon, K.D., et al. Simultaneous blockade of VEGF and DLL4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis. mAbs 2016, 8, 892-904. [CrossRef] [PubMed]
96. Moores, S.L., Chiu, M., Bushey, B.S., Chevalier, K., Luistro, L., Dorn, K., Brezski, R.J., Haytko, P., Kelly, T., Wu, S.J., et al. A novel bispecific antibody targeting EGFR and cMet that is effective against EGFR inhibitor-resistant lung tumors. Cancer Res. 2016, 76, 3942-3953. [CrossRef] [PubMed]
97. Shima, M., Hanabusa, H., Taki, M., Matsushita, T., Sato, T., Fukutake, K., Fukazawa, N., Yoneyama, K., Yoshida, H., Nogami, K. Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A. N. Engl. J. Med. 2016, 374, 2044-2053. [CrossRef] [PubMed]
98. Nogami, K. Bispecific antibody mimicking factor VIII. Thromb. Res. 2016, 141, S34-S35. [CrossRef]
99. Florio, M., Gunasekaran, K., Stolina, M., Li, X., Liu, L., Tipton, B., Salimi-Moosavi, H., Asuncion, F.J., Li, C., Sun, B., et al. A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair. Nat. Commun. 2016, 7, 11505. [CrossRef] [PubMed]
100. Thaden, J.T., Keller, A.E., Shire, N.J., Camara, M.M., Otterson, L., Huband, M., Guenther, C.M., Zhao, W., Warrener, P., Stover, C.K., et al. Pseudomonas aeruginosa bacteremic patients exhibit nonprotective antibody titers against therapeutic antibody targets PCRV and PSL exopolysaccharide. J. Infect. Dis. 2016, 213, 640-648. [CrossRef] [PubMed]
101. DiGiandomenico, A., Keller, A.E., Gao, C., Rainey, G.J., Warrener, P., Camara, M.M., Bonnell, J., Fleming, R., Bezabeh, B., Dimasi, N., et al. A multifunctional bispecific antibody protects against pseudomonas aeruginosa. Sci. Transl. Med. 2014, 6, 262ra155. [CrossRef] [PubMed]
102. Yu, Y.J., Atwal, J.K., Zhang, Y., Tong, R.K., Wildsmith, K.R., Tan, C., Bien-Ly, N., Hersom, M., Maloney, J.A., Meilandt, W.J., et al. Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates. Sci. Transl. Med. 2014, 6, 261ra154. [CrossRef] [PubMed]
103. Huang, Y., Yu, J., Lanzi, A., Yao, X., Andrews, C.D., Tsai, L., Gajjar, M.R., Sun, M., Seaman, M.S., Padte, N.N., et al. Engineered bispecific antibodies with exquisite HIV-1-neutralizing activity. Cell 2016, 165, 1621-1631. [CrossRef] [PubMed]
104. Bournazos, S., Gazumyan, A., Seaman, M.S., Nussenzweig, M.C., Ravetch, J.V. Bispecific anti-HIV-1 antibodies with enhanced breadth and potency. Cell 2016, 165, 1609-1620. [CrossRef] [PubMed]
105. Gramer, M.J., van den Bremer, E.T., van Kampen, M.D., Kundu, A., Kopfmann, P., Etter, E., Stinehelfer, D., Long, J., Lannom, T., Noordergraaf, E.H., et al. Production of stable bispecific IgG1 by controlled FAB-arm exchange. mAbs 2014, 5, 962-973. [CrossRef] [PubMed]